R01HL162661

Parametric Response Mapping (PRM) for the detection of chronic lung injury in hematopoietic cell transplant recipients - Abstract.

Chronic lung dysfunction (CLD) is a potentially severe complication of bone marrow transplantation (BMT), particularly prevalent in patients who develop chronic graft versus host disease (GVHD) post-BMT. The development of CLD is associated with a 20%-40% long-term survival rate, with the majority of patients diagnosed with CLD only after they have developed significant (and potentially irreversible) lung pathology.

There is a critical need to identify CLD earlier in its clinical course, at a stage when treatment may prove beneficial to patients. PRM is a novel computed tomography (CT) based methodology that, when applied to standard CT scans, is capable of identifying and quantifying a variety of lung disease subtypes in patients. This technology was initially developed at Michigan Medicine over 10 years ago for patients with chronic obstructive pulmonary disease (COPD).

In both single-center and multicenter trials, PRM has demonstrated efficacy for the identification of CLD in adult BMT patients. Our central hypothesis is that PRM can identify patients with chronic GVHD who are at high risk for the development of CLD. We propose an observational study to examine PRM in adult and pediatric subjects (= 3 years in age) with chronic GVHD post-BMT.

To test our hypothesis, we have established 3 specific aims. In the first two, we will examine PRM values at two main time points: at the onset of chronic GVHD (Aim 1) and at the onset of CLD (Aim 2), with CLD defined by standard NIH criteria. In Aim 3, we will develop a machine learning model that will incorporate serologic and pulmonary function test (PFT) biomarkers with PRM values to develop a composite biomarker strategy.

Upon completion of our current proposal, we will establish PRM as a predictor of CLD in adult BMT patients. In addition, the PRM, PFT, and serologic data obtained from pediatric BMT patients will provide a data bank for future research in this population. Historically, the ability to identify CLD in pediatric patients has been PFT-dependent, with PFTs technically challenging to conduct in young children.

The use of PRM as a diagnostic indicator of CLD in pediatric BMT patients will be a major advance of this proposal. Finally, our proposal takes our PRM methodology forward in adults, allowing us to study the trajectory of lung disease in adult BMT recipients with chronic GVHD, and following the onset of CLD.

Regents Of The University Of Michigan

THE DIVISION OF LUNG DISEASES SUPPORTS RESEARCH AND RESEARCH TRAINING ON THE CAUSES, DIAGNOSIS, PREVENTION, AND TREATMENT OF LUNG DISEASES AND SLEEP DISORDERS. RESEARCH IS FUNDED THROUGH INVESTIGATOR-INITIATED AND INSTITUTE-INITIATED GRANT PROGRAMS AND THROUGH CONTRACT PROGRAMS IN AREAS INCLUDING ASTHMA, BRONCHOPULMONARY DYSPLASIA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CYSTIC FIBROSIS, RESPIRATORY NEUROBIOLOGY, SLEEP AND CIRCADIAN BIOLOGY, SLEEP-DISORDERED BREATHING, CRITICAL CARE AND ACUTE LUNG INJURY, DEVELOPMENTAL BIOLOGY AND PEDIATRIC PULMONARY DISEASES, IMMUNOLOGIC AND FIBROTIC PULMONARY DISEASE, RARE LUNG DISORDERS, PULMONARY VASCULAR DISEASE, AND PULMONARY COMPLICATIONS OF AIDS AND TUBERCULOSIS. THE DIVISION IS RESPONSIBLE FOR MONITORING THE LATEST RESEARCH DEVELOPMENTS IN THE EXTRAMURAL SCIENTIFIC COMMUNITY AS WELL AS IDENTIFYING RESEARCH GAPS AND NEEDS, OBTAINING ADVICE FROM EXPERTS IN THE FIELD, AND IMPLEMENTING PROGRAMS TO ADDRESS NEW OPPORTUNITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.

93.837 - Cardiovascular Diseases Research

National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]

Ann Arbor, Michigan 481091276 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 259% from $870,211 to $3,121,383.